RT Journal Article
SR Electronic
T1 Prospectively validated augmented intelligence for disease-agnostic predictions of clinical success for novel therapeutics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.14.22272372
DO 10.1101/2022.03.14.22272372
A1 Lovetrue, Bragi
A1 Lovetrue, Idonae
YR 2022
UL http://medrxiv.org/content/early/2022/04/11/2022.03.14.22272372.abstract
AB Standalone artificial intelligence has not alleviated the long-term bottleneck of linearly extracting new knowledge from exponentially growing biological data, which has severely limited clinical success rates for drug discovery. We developed a ‘virtual patient’ augmented intelligence model that functionally reconstructed human physiology and human pathogenesis for high-fidelity simulations of drug-body interactions. We examined the clinical utility of ‘virtual patient’ in prospective predictions of clinical efficacy and safety of novel therapeutics regardless of prior clinical data availability, through a 24- month, public, prospective, large-scale, unbiased, and real-world validation study. ‘Virtual patient’ achieved 90.1% sensitivity and 82.0% precision with a 99% confidence across all major therapeutic areas, representing its capability of discovering 90.1% of all possible drug-indication pairs that could bring clinical benefits to patients, and its potential of increasing tenfold the baseline clinical success rate from 7.9% to 82.0%. ‘Virtual patient’ represents a methodological shift of drug discovery especially for age-related diseases by doing away with animal experiments whose data are hard to reproduce, virtualizing human trials whose outcomes are doomed to failure, initiating human trials whose participants are likely to benefit, and reducing R&D cycles and costs while increasing clinical efficacy and safety.One-Sentence Summary A prospectively validated ‘virtual patient’ achieved a 10.4-fold improvement in the clinical success rate for new drugs across all major diseases with 99% confidence.Competing Interest StatementThis study was funded by Demiurge Technologies AG. B.L. and I.L. are employees, board members, and shareholders of Demiurge Technologies AG.Funding StatementThis study did not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.